The intent-to-treat population comprised 781 patients in the venlafaxine ER group ( 65 % women ) and 266 patients in the fluoxetine group ( 61 % women ) ; 64 % of all women were premenopausal , and 25 % were postmenopausal ( 5 % perimenopausal ; not analyzed ) .